会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Device and method for interfacing video devices over a fiber optic link
    • 通过光纤链路连接视频设备的设备和方法
    • US07061405B2
    • 2006-06-13
    • US10966823
    • 2004-10-15
    • Michael R. BoydJason J. BeaudoinVincent Mui
    • Michael R. BoydJason J. BeaudoinVincent Mui
    • H03M7/00
    • H04B10/278G09G5/006H04B10/27H04N5/765H04N5/77H04N5/775H04N5/85
    • A system and method for interfacing video devices over a link where electronic digital video data having a quantity (n) of bits of parallel data transmitted electronically at a first clock rate (R1) is converted to a stream of electronic serial data that is transmitted a second clock rate (R2=R1×n). The stream of electronic serial data is transmitted over a link that can be a fiber optic link or include one or more conductors. A receiver is employed to convert the data transmitted over the link into an output data stream having (n) bits of parallel data transmitted electronically at the first clock rate (R1). If the link is a fiber optic link, the receiver can convert the data transmitted over the link into to a second stream electronic serial data that is transmitted at the second clock rate (R2) and then to the output data stream.
    • 一种用于通过链路来连接视频设备的系统和方法,其中具有以第一时钟速率(R 1> 1)以电子方式发送的并行数据量的数量(n)的电子数字视频数据被转换为流 以及第二时钟速率(R 2 2 = R 1 x n)的电子串行数据。 电子串行数据流通过可以是光纤链路的链路传输,或者包括一个或多个导体。 采用接收机将通过链路发送的数据转换成具有以第一时钟速率(R 1> 1)电子发送的(n)个并行数据位的输出数据流。 如果链路是光纤链路,则接收机可以将通过链路传输的数据转换成以第二时钟速率(R 2> 2)发送的第二流电子串行数据,然后到 输出数据流。
    • 3. 发明授权
    • Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds
    • 包括液泡型(H +) - ATP酶抑制化合物的骨质疏松症治疗方法
    • US07381744B1
    • 2008-06-03
    • US09914708
    • 2000-03-02
    • Michael R. Boyd
    • Michael R. Boyd
    • A61K31/335A61K31/70C07D313/00
    • A61K31/366A61K31/357A61K31/365A61K31/39A61K31/536A61K45/06
    • The present invention provides vacuolar-type (H+)-ATPase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of the present invention comprises a compound of the present invention and a carrier. The method of the present invention includes administering a vacuolar-type (H+)-ATPase inhibiting-effective amount of a compound of the present invention. The compound of the present invention has formula (I) wherein R1 and R2 are H, saturated or unsaturated alkyl, aryl, R6CH2—, R6CO—, or R6SO2—, wherein R6 is H, saturated or unsaturated alkyl, or aryl; R3 is H, alkyl, aryl, an oxime, or an oxime methyl ether; the aromatic ring is unsubstituted or substituted; and Z is a contiguous linker comprising a chain of 0-10 atoms which, together with the five atoms beginning with the carbon of the aromatic ring in meta-relationship with OR1 and ending with the carbon directly attached to the alkyl oxygen of the lactone, integrally form a 5-17 membered ring; or a pharmaceutically acceptable salt, an ester, or a prodrug thereof.
    • 本发明提供液泡型(H +) - ATP酶抑制化合物,其组合物,以及使用它们来治疗或预防通过抑制液泡型(H +) - ATP酶可治疗的病症的方法。 本发明的组合物包含本发明的化合物和载体。 本发明的方法包括施用液泡型(H +) - ATP酶抑制有效量的本发明化合物。 本发明的化合物具有式(I),其中R 1和R 2是H,饱和或不饱和的烷基,芳基,R 6, CH 2 - , - NR 6 - , - 或SO 6 SO 2 - ,其中R 6 H是饱和或不饱和的烷基或芳基; R 3是H,烷基,芳基,肟或肟甲基醚; 芳环是未取代的或取代的; 并且Z是包含0-10个原子的链的连续接头,其与从OR 1开始的五个原子与OR 1的间隔关系以及直接连接的碳结束 与内酯的烷基氧一体形成5-17元环; 或其药学上可接受的盐,酯或前药。
    • 5. 发明授权
    • Monomeric and dimeric arylisoquinoline alkaloids and derivatives thereof
    • 单体和二聚芳基异喹啉生物碱及其衍生物
    • US6140339A
    • 2000-10-31
    • US1801
    • 1997-12-31
    • Gerhard BringmannMichael R. BoydMatthias Wenzel
    • Gerhard BringmannMichael R. BoydMatthias Wenzel
    • A61K31/47A61K31/4725A61P33/06C07D217/02C07D217/04C07D217/24C07D401/04C07D401/10C07D491/04A61K31/472C07D217/06
    • C07D491/04A61K31/47C07D217/02C07D217/04C07D217/24
    • The present invention provides new monomeric derivatives of the C-8'-7 linked naphthylisoquinoline alkaloid dioncophylline D. The invention also provides new C-4 substituted monomeric arylisoquinoline alkaloid derivatives. The present invention furthermore provides novel dimeric arylisoquinoline alkaloids comprised of coupled first and second arylisoquinoline monomers, wherein either or both of said monomer(s) is (are) monomeric compound(s) of the present invention. Monomeric and dimeric compounds of the present invention have medically useful properties, such as antimicrobial properties, more specifically such as antimalarial and antiviral properties. Monomeric compounds of the present invention are also useful as building blocks or intermediates for synthesis of novel dimeric arylisoquinoline alkaloids. Monomeric and dimeric compounds of the present invention may be obtained in substantially pure form by total synthesis, partial synthesis, or derivatization from known synthetic or naturally occurring compounds, and by isolation and purification from plants of the Dioncophyllaceae and Ancistrocladaceae families.
    • 本发明提供了C-8'-7连接的萘基异喹啉生物碱二萜类植物D的新单体衍生物。本发明还提供新的C-4取代的单体芳基异喹啉生物碱衍生物。 本发明还提供由偶联的第一和第二芳基异喹啉单体组成的新型二聚芳基异喹啉生物碱,其中所述单体中的一种或两种是本发明的单体化合物。 本发明的单体和二聚体化合物具有医学上有用的性质,例如抗微生物性质,更具体地,例如抗疟疾和抗病毒性质。 本发明的单体化合物也可用作合成新型二聚芳基异喹啉生物碱的结构单元或中间体。 本发明的单体和二聚体化合物可以通过从合成或天然存在的化合物的全部合成,部分合成或衍生化,以及通过从Dioncophyllaceae和Ancistrocladaceae家族的植物中分离和纯化而以基本上纯的形式获得。